- Quotient Sciences and Intrepid Labs have entered a multi-year partnership to integrate AI-driven formulation design into early drug development.
- The collaboration gives Quotient Sciences access to the ANDROMEDA machine learning model to support formulation optimisation and accelerate clinical readiness.
Quotient Sciences and Intrepid Labs have entered a multi-year strategic partnership aimed at advancing the use of artificial intelligence in early drug development. The agreement grants Quotient Sciences access to Intrepid’s ANDROMEDA machine learning platform, which is designed to support the development and optimisation of drug product clinical performance.
The collaboration answers the question of how both organisations intend to use AI to improve early formulation design, reduce experimental burden and guide data-driven decision-making. According to the announcement, ANDROMEDA uses a proprietary machine learning algorithm to model and explore formulation options, with potential for client-specific or aggregated models to improve predictivity.
The partnership builds on an existing relationship in which Intrepid’s platform was incorporated into Quotient Sciences’ Translational Pharmaceutics® offering. This earlier integration sought to accelerate formulation selection and shorten the time required to progress new drug products into clinical development.
Customers will be able to draw on Quotient Sciences’ formulation development, GMP manufacturing and early-phase clinical testing capabilities alongside Intrepid Labs’ expertise in AI-enabled formulation science. Each project will be supported by an independent AI instance to ensure confidentiality and data protection.
“This is a truly unique offering. It blends Quotient’s decades of experience in drug product development and accelerated clinical testing using Translational Pharmaceutics® with Intrepid’s cutting-edge AI capabilities to reduce drug substance requirements in early development, shorten development cycles, increase speed to clinic, and deliver more informed decision-making for pharmaceutical companies.”
Thierry Van Nieuwenhove, CEO of Quotient Sciences
Initial pilot projects comparing traditional and AI-assisted development approaches will begin immediately before a broader rollout. Both organisations plan to evaluate further applications as AI adoption continues to grow across pharmaceutical R&D.
